Valeria Manca

Dr. Valeria Manca


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2024 in Viruses
Verified
Journal Article
Open access
PDF file
VMValeria Manca
Valeria Manca
ACAnnalisa Chianese
Annalisa Chianese
VPVanessa Palmas
Vanessa Palmas
FEFederica Etzi
Federica Etzi
CZCarla Zannella
Carla Zannella
GSGiuseppina Sanna
Giuseppina Sanna
Severe acute respiratory syndrome-related Coronavirus 2 (SARS-CoV-2) has infected more than 762 million people to date and has caused approximately 7 million deaths all around the world, involving more than 187 countries. Although currently available vaccines show high efficacy in preventing severe respiratory complications in infected patients, the high number of mutations in the S proteins of the current variants is responsible for the high level of immune evasion and transmissibility of the virus and the reduced effectiveness of acquired immunity. In this scenario, the development of safe and effective drugs of synthetic or natural origin to suppress viral replication and treat acute forms of COVID-19 remains a valid therapeutic challenge. Given the successful history of flavonoids-based drug discovery, we developed esters of substituted cinnamic acids with quercetin to evaluate their in vitro activity against a broad spectrum of Coronaviruses. Interestingly, two derivatives, the 3,4-methylenedioxy 6 and the ester of acid 7, have proved to be effective in reducing OC43-induced cytopathogenicity, showing interesting EC50s profiles. The ester of synaptic acid 7 in particular, which is not endowed with relevant cytotoxicity under any of the tested conditions, turned out to be active against OC43 and SARS-CoV-2, showing a promising EC50. Therefore, said compound was selected as the lead object of further analysis. When tested in a yield reduction, assay 7 produced a significant dose-dependent reduction in viral titer. However, the compound was not virucidal, as exposure to high concentrations of it did not affect viral infectivity, nor did it affect hCoV-OC43 penetration into pre-treated host cells. Additional studies on the action mechanism have suggested that our derivative may inhibit viral endocytosis by reducing viral attachment to host cells.

4 January 2026 in Viruses
Verified
Journal Article
Open access
PDF file
VMValeria Manca
Valeria Manca
LLLaura Locci
Laura Locci
Roberta IbbaRoberta Ibba
Roberta Ibba
LSLaura Sanna
Laura Sanna
Ilenia LupinuIlenia Lupinu
Ilenia Lupinu
ACAntonio Carta
Antonio Carta
Introduction: Despite the impressive progress carried out in the field of biomedical sciences in recent decades, the incidence of emerging and neglected lethal viral infections mainly belonging to the Coronaviridae, Filoviridae, Arenaviridae, Bunyaviridae, and Paramyxoviridae families has considerably impaired human health. The worldwide vaccination campaign at the end of the 1970s determined the eradication of smallpox. However, the growing number of cases of diseases linked to orthopoxvirus diseases, such as the recent epidemic of monkeypox zoonosis in various countries around the world, has increased the need for knowledge of these viral pathogens. To date, there is no specific treatement for Monkeypox virus (MPXV) infection. However, several antiviral drugs used to treat Smallpox and other viral infections could also be beneficial for Monkeypox disease. In this study we report the design and synthesis of new, variously substituted benzimidazole derivatives and the evaluation of their cytotoxicity and antiviral activity against representatives of the Orthopoxvirus genus, Vaccinia Virus (VV), closely related to variola virus and MPXV. Methods: A combination of cell-based assays and experimental techniques was used to investigate the cytotoxicity, antiviral activity, and mechanisms of action of the most interesting compound. Results: In our study, new, variously substituted benzimidazoles showed interesting EC50 values against vaccinia and MPXV and a cytotoxic profile in the high micromolar range. Conclusions: Our work shows that the new tested benzimidazole derivatives possess appealing activity and selectivity, accompanied by low cytotoxicity. These results set a valid foundation with which to identify potent and selective anti-Poxvirus agents.

14 June 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
GCGiulia Costanzo
Giulia Costanzo
GSGiuseppina Sanna
Giuseppina Sanna
FPFrancesco Pes
Francesco Pes
CDCarla Maria Deiana
Carla Maria Deiana
ALAndrea Giovanni Ledda
Andrea Giovanni Ledda
Davide FirinuDavide Firinu
Davide Firinu
Immunization against COVID-19 is needed in patients with immune-mediated inflammatory diseases (IMIDs). However, data on long-term immunity kinetics remain scarce. This study aimed to compare the humoral and cellular response to COVID-19 in patients with immune-mediated inflammatory diseases (IMIDs) compared to healthy controls. We compared the humoral and cellular response to SARS-Cov-2 elicited by vaccination and/or infection in a prospective cohort of 20 IMID patients compared with a group of 21 healthcare workers (HCWs). We assessed immunity before and after the third and fourth dose of BNT162b2 or after COVID-19 infection using quantitative IgG anti-SARS-CoV-2 Spike antibody (anti-S-IgG), neutralization assay, and specific interferon-gamma (IFN-g) release assay (IGRA). The responses were compared with those of healthy controls. The two groups were similar in age and total exposure, becoming infected for the first time, mainly after the third dose. Neutralizing antibodies and IGRA were negative in 9.5% of IMID patients but not in any HCWs. No significant difference was found between neutralization titers to BA.1 in the IMID and the HCW groups. The study highlights the SARS-CoV-2 immunological responses in healthy controls and IMID patients, suggesting that the combined stimuli of vaccination and infection in IMID patients could promote a more profound immunological response.

1 March 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
RPRebecca Piras
Rebecca Piras
LVLuca Virdis
Luca Virdis
VMValeria Manca
Valeria Manca
MCMarta Cogoni
Marta Cogoni
VPVanessa Palmas
Vanessa Palmas
LRLuay J. Rashan
Luay J. Rashan
In recent years, the emergence of drug-resistant pathogens and the limitations of current therapies have highlighted the need for innovative strategies to combat emerging viral infections. Natural compounds, derived from plants, are playing an increasingly significant role in the research of novel and effective therapies. Boswellia sacra, a frankincense-producing tree widely distributed in Yemen and Oman, and Nerium oleander, a common ornamental and medicinal plant, are examples of plants with well-documented antimicrobial properties. Their extracts have demonstrated good activity against a wide range of infections, which is attributed to the anti-inflammatory and immunomodulatory compounds they contain. Based on these findings, we assessed, in vitro, the broad-spectrum antiviral activity of combined extracts obtained from Boswellia sacra and Nerium oleander. The extract mixture NOBS7(1) was found to be active against the respiratory virus RSV, Herpesvirus simplex type 1, and Coxsackievirus 5. Furthermore, a combination of cell-based assays was performed to provide additional insights into their potential mechanism of action.